21 – 30 of 80
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
C-JUN INTERVENES WITH DOCETAXEL THERAPY IN CASTRATION-RESISTANT PROSTATE CANCER: AR STILL MATTERS
2011) 26th Annual Congress of the European Association of Urology In European Urology Supplements 10(2). p.294-294(
- Contribution to journal › Published meeting abstract
-
Mark
Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
Label retaining cells and stem cell marker expression in the developing and adult mouse prostate
(
- Contribution to journal › Published meeting abstract
-
Mark
Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy
(
- Contribution to journal › Article
-
Mark
Burden of metastatic bone disease from genitourinary malignancies
(
- Contribution to journal › Scientific review
-
Mark
European Association of Urology. Position statement on screening for prostate cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Reply to Tomasz Drewa's Letter to the Editor re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
(
- Contribution to journal › Letter
-
Mark
Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model.
(
- Contribution to journal › Article
-
Mark
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature.
(
- Contribution to journal › Article
-
Mark
PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population.
(
- Contribution to journal › Article